Health Care [ 1/12 ] | Biotechnology [ 12/73 ]
NASDAQ | Common Stock
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.
Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes.
The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel.
ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 10, 25 | -0.12 Increased by +15.43% | -0.15 Increased by +17.86% |
| Aug 12, 25 | -0.13 Increased by +18.75% | -0.15 Increased by +13.33% |
| May 12, 25 | -0.13 Increased by +18.75% | -0.16 Increased by +18.75% |
| Mar 17, 25 | -0.16 Decreased by -77.78% | -0.15 Decreased by -6.67% |
| Nov 10, 24 | -0.14 Increased by +21.17% | -0.15 Increased by +5.40% |
| Aug 9, 24 | -0.16 Decreased by -14.29% | -0.17 Increased by +5.88% |
| May 10, 24 | -0.16 Increased by 0.00% | -0.18 Increased by +11.11% |
| Mar 22, 24 | -0.09 Increased by +18.18% | -0.17 Increased by +47.06% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 25 | 217.00 K Increased by +N/A% | -16.47 M Increased by +8.05% | Decreased by -7.59 K% Decreased by N/A% |
| Jun 30, 25 | 221.00 K Increased by +N/A% | -16.55 M Decreased by -32.35% | Decreased by -7.49 K% Decreased by N/A% |
| Mar 31, 25 | 230.00 K Increased by +N/A% | -16.73 M Decreased by -76.30% | Decreased by -7.28 K% Decreased by N/A% |
| Dec 31, 24 | 76.00 K Decreased by -98.31% | -21.28 M Decreased by -273.23% | Decreased by -28.00 K% Decreased by -21.97 K% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -17.91 M Decreased by -63.06% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -12.51 M Decreased by -37.16% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -9.49 M Increased by +1.79% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 4.49 M Increased by +N/A% | -5.70 M Increased by +12.12% | Decreased by -126.86% Decreased by N/A% |